Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
Catecholamine-degrading enzyme COMT inhibitor was administered intraperitoneally. Behavioral analysis showed that hyperalgesia developed in the hypercatecholaminergic model. beta2 adrenergic receptors are expressed in small neurons of the dorsal root ganglia and their expression was increased in the hypercatecholaminergic model. The beta2 adrenergic receptor antagonists had no apparent effect on hyperalgesia caused by hypercatecholaminemia. GRK2, which is involved in the regulation of receptor signaling, tended to increase in the hypercatecholaminergic model, but the change was not statistically significant.
|